Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one

被引：17

作者：

Velaparthi, Upender ^{[1
]}

Saulnier, Mark G. ^{[1
]}

Wittman, Mark D. ^{[1
]}

Liu, Peiying ^{[1
]}

Frennesson, David B. ^{[1
]}

Zimmermann, Kurt ^{[1
]}

Carboni, Joan M. ^{[4
]}

Gottardis, Marco ^{[4
]}

Li, Aixin ^{[4
]}

Greer, Ann ^{[4
]}

Clarke, Wendy ^{[2
]}

Yang, Zheng ^{[3
]}

Menard, Krista ^{[4
]}

Lee, Francis Y. ^{[4
]}

Trainor, George ^{[4
]}

Vyas, Dolatrai ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Dept Discovery Chem, Wallingford, CT 06492 USA

[2] Bristol Myers Squibb Co, Dept Metab & Pharmacokinet, Wallingford, CT 06492 USA

[3] Bristol Myers Squibb Co, Dept Metab & Pharmacokinet, Princeton, NJ 08543 USA

[4] Bristol Myers Squibb Co, Dept Oncol Drug Discovery, Princeton, NJ 08543 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 10期

关键词：

Insulin-like growth factor-1 receptor (IGF-1R); Kinases; IGF; Benzimidazole; Piperazine; CYP3A4; inhibition; Solubility; VIVO ANTITUMOR-ACTIVITY; DISCOVERY; BMS-536924;

D O I：

10.1016/j.bmcl.2010.03.057

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of 3-[6-(4-substitued-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one were synthesized to modulate CYP3A4 inhibition and improve aqueous solubility of our prototypical compound BMS-536924 (1), while maintaining potent IGF-1R inhibitory activity. Structure-activity and structure-solubility studies led to the identification of BMS-577098 (27), which demonstrates oral in vivo efficacy in animal models. The improvement was achieved by replacing morpholine with more polar bio-isoster piperazine and modulating the basicity of distal nitrogen with appropriate substitutions. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：3182 / 3185

页数：4

共 50 条

[21] Synthesis and Antimicrobial Activity of Novel Substituted 4-[3-(1H-Benzimidazol-2-yl)-4-hydroxybenzyl]-2-(1H-benzimidazol-2-yl)phenol Derivatives
V. Anil
B. Shankar
G. Bharath
P. Jalapathi
Russian Journal of General Chemistry, 2017, 87 : 3017 - 3022
[22] Synthesis and antimicrobial activity of novel substituted 4-[3-(1H-benzimidazol-2-yl)-4-hydroxybenzyl]-2-(1H-benzimidazol-2-yl)phenol derivatives
V. Anil
B. Shankar
G. Bharath
P. Jalapathi
Russian Journal of General Chemistry, 2017, 87 : 2648 - 2653
[23] Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors
Buchanan, John L.
Newcomb, John R.
Carney, David P.
Chaffee, Stuart C.
Chai, Lilly
Cupples, Rod
Epstein, Linda F.
Gallant, Paul
Gu, Yan
Harmange, Jean-Christophe
Hodge, Kathy
Houk, Brett E.
Huang, Xin
Jona, Janan
Joseph, Smriti
Jun, H. Toni
Kumar, Rakesh
Li, Chun
Lu, John
Menges, Tom
Morrison, Michael J.
Novak, Perry M.
van der Plas, Simon
Radinsky, Robert
Rose, Paul E.
Sawant, Satin
Sun, Ji-Rong
Surapaneni, Sekhar
Turci, Susan M.
Xu, Keyang
Yanez, Evelyn
Zhao, Huilin
Zhu, Xiaotian
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (08) : 2394 - 2399
[24] 3-(Adamantan-1-yl)-4-ethyl-1-{[4-(2-methoxyphenyl)piperazin-1-yl]methyl}1H-1,2,4-triazole-5(4H)-thione
El-Emam, Ali A.
Al-Tuwaijri, Hanaa M.
Al-Abdullah, Ebtehal S.
Kumar, C. S. Chidan
Fun, Hoong-Kun
ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2014, 70 : O25 - +
[25] Methyl 3-[(1H-benzimidazol-1-yl)methyl]-1-methyl-4-(4-methylphenyl)-2′-oxopyrrolidine-2-spiro-3′-1-benzimidazole-3-carboxylate
Selvanayagam, S.
Sridhar, B.
Ravikumar, K.
Kathiravan, S.
Raghunathan, R.
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2010, 66 : O2508 - U1905
[26] Green Synthesis and Antimicrobial Activity of 3-{1-[(1-Aryl-1H-1,2,3-triazol-4-yl)methyl]-1H-benzimidazol-2-yl}-2-(pyrrolidin-1-yl)quinoline Derivatives
Pradeep, M.
Vishnuvardhan, M.
Ganesh, A.
Thalari, Gangadhar
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, 2024, 60 (06) : 1129 - 1135
[27] Design, synthesis and evaluation of 6-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenanthridine analogues as antimycobacterial agents
Nagesh, Hunsur Nagendra
Naidu, Kalaga Mahalakshmi
Rao, Damarla Harika
Sridevi, Jonnalagadda Padma
Sriram, Dharmarajan
Yogeeswari, Perumal
Sekhar, Kondapalli Venkata Gowri Chandra
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (24) : 6805 - 6810
[28] 3-Benzyl-1-{[3-(4-chlorophenyl)isoxazol5-yl]methyl}-1H-benzimidazol-2(3H)one
Rodi, Youssef Kandri
Haoudi, Amal
Capet, Frederic
Rolando, Christian
El Ammari, Lahcen
ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2013, 69 : O1451 - +
[29] In Vitro and InSilico Evaluation of 2-(1H-Benzo[d]imidazol-2-yl)-3-(4-(piperazin-1-yl)phenyl)propanenitrile as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Sarita, K.
Kumar, N.
Agrawal, A.
Mali, S. N.
Sharma, S.
RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2024, 50 (04) : 1563 - 1572
[30] 3-Methyl-1-(pyridin-2-yl)-4-(1-pyridin-2-yl-3-methyl-1H-pyrazol-5-yl)-2H-3-pyrazolin-5(1H)-one
Djerrari, B
Essassi, EM
Fifani, J
Pierrot, M
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2001, 57 : O1126 - O1127

← 1 2 3 4 5 →